Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 7:39 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1897–1920 of 3,580 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: patch Clear all

Conditions: Smoking, Anxiety Disorders, Depression Disorders
Interventions: Nicotine Patch, Depression and Anxiety Smoking Cessation Treatment, Educational-Support Psychotherapy; Drug · Behavioral
Lead sponsor: University of Houston; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Decompensated Heart Failure
Interventions: AVIVO™ PiiX Patch Monitor System; Device
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 7
States / cities: La Jolla, California • Tampa, Florida • Saint Paul, Minnesota + 4 more

Conditions: Cervical Intraepithelial Neoplasia, Uterine Cervical Dysplasia
Interventions: A-007; Drug
Lead sponsor: Tigris Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 5
States / cities: Tucson, Arizona • Costa Mesa, California • Boynton Beach, Florida + 2 more

Conditions: Suicidal Ideation
Interventions: Estradiol Transdermal Patch 0.1 mg/24 hrs, Oral Micronized Progesterone, Inactive Clear Patch, Placebo capsule; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Smoking Cessation
Interventions: Tobacco Tactics Intervention, Usual Care; Behavioral · Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 1,528 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 6
States / cities: Grand Rapids, Michigan • Livonia, Michigan • Muskegon, Michigan + 2 more

Conditions: Small Cell Lung Cancer Extensive Stage, Brain Metastases, Solid Tumor, Adult, Thoracic Cancer, Sarcoma,Soft Tissue, HNPCC
Interventions: Cohort A: Extensive Stage Small Cell Lung Cancer (ES-SCLC) Thoracic Tumor PULSAR (Personalized ultrahypofractionated stereotactic ablative radiotherapy), Cohort B: Brain metastasis PULSAR (Personalized ultrahypofractionated stereotactic ablative radiotherapy), Cohort C: Sarcoma Pre-Operative PULSAR, Cohort D: Resectable Head & Neck Squamous Cell Carcinoma (HNSCC) PULSAR/SAbR; Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Lagophthalmos
Interventions: Tarsus Patch; Device
Lead sponsor: Angeline Nguyen; Other
Eligibility: Up to 17 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Brain Tumors
Interventions: 5-aminolevulinic acid; Drug
Lead sponsor: David W. Roberts; Other
Eligibility: 21 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Nicotine Dependence
Interventions: Juul Electronic cigarette, Very Low Nicotine Cigarettes, Active Nicotine Patch, Placebo Patch; Device · Other · Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 21 Years and older
Enrollment: 209 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Madison, Wisconsin • Milwaukee, Wisconsin

Conditions: Pigmented Skin Lesion
Interventions: Dermal Cooling System; Device
Lead sponsor: R2 Dermatology; Industry
Eligibility: 18 Years and older
Enrollment: 377 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Walnut Creek, California

Conditions: Smoking Cessation, Cancer
Interventions: Transdermal Nicotine Patch, Standard Telephone Counseling, Varenicline, Cancer-Targeted Telephone Counseling, Mailed Information about Standard Care Resources; Drug · Behavioral · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Hypoactive Sexual Desire Disorder
Interventions: Testosterone Transdermal System, Placebo patch; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 45 Years to 70 Years · Female only
Enrollment: 1,271 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 115
States / cities: Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 97 more

Conditions: Molluscum Contagiosum, Skin Disease
Interventions: cantharidin's vehicle, Cantharidin 0.7%; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 5 Years to 10 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Attention Deficit Hyperactivity Disorder, INSOMNIA
Interventions: Daytrana; Drug
Lead sponsor: Cox Health Systems; Other
Eligibility: 6 Years to 12 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Turner Syndrome, Primary Ovarian Insufficiency
Interventions: Estradiol transdermal patch 0.025mg/24 hours- 1/8th fractionated patch; Drug
Lead sponsor: Children's National Research Institute; Other
Eligibility: 8 Years to 12 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Basal Cell Carcinoma
Interventions: Optical Coherence Tomography (OCT), Curettage & Desiccation (C&D) Procedure; Device · Procedure
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Miami, Florida

Conditions: HSIL, High-Grade Squamous Intraepithelial Lesions, Human Papilloma Virus Infection, HIV Infection, Anal Cancer, Anus Neoplasm
Interventions: Topical ABI-1968 cream; Drug
Lead sponsor: Antiva Biosciences; Industry
Eligibility: 27 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Breast Cancer, Breast Neoplasms
Interventions: Focused Ultrasound, Gemcitabine and Focused Ultrasound; Device · Other
Lead sponsor: Patrick Dillon, MD; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Rectal Carcinoma
Interventions: 5FU, Radiation, Surgery of resectable lesions, Irinotecan; Drug · Radiation · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2010
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Breast Cancer
Interventions: Phase Contrast Mammography; Other
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 40 Years and older · Female only
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Graft Versus Host Disease, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Echocardiography, Fludarabine, Melphalan, Multigated Acquisition Scan, Questionnaire Administration, Tacrolimus, Vedolizumab; Procedure · Drug · Other + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Duarte, California

Conditions: Cutaneous Lupus Erythematosus
Interventions: UVA1 radiation treatment; Device
Lead sponsor: Ben Chong; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Sebaceous Hyperplasia, Skin Abnormalities, Skin Lesion
Interventions: Nano-Pulse Stimulation (NPS); Device
Lead sponsor: Pulse Biosciences, Inc.; Industry
Eligibility: 21 Years to 75 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 6
States / cities: Scottsdale, Arizona • Sacramento, California • Santa Monica, California + 3 more

Conditions: Skin Sensitization
Interventions: IV Clear™, Tegaderm CHG™, Silicone Vehicle Control Dressing; Device
Lead sponsor: Covalon Technologies Inc.; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 216 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: St. Petersburg, Florida

Search by objective public record fields.

Smoking Cessation for Depression and Anxiety Treatment

REducing 30-day ADMIssions in posT-discharge Subjects (READMIT)

A Two-Stage Phase 2 Study Of A-007 Topical Gel in High-Grade Squamous Intraepithelial Lesions (HSIL)

Effect of Perimenstrual Ovarian Steroid Supplementation on Perimenstrual Suicidality

Dissemination of Tobacco Tactics for Hospitalized Smokers

Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)

Nictavi Tarsus Patch for Managing Lagophthalmos

Fluorescence Guided Resection of Brain Tumors

Impact of Alternative Nicotine-Delivery Products on Combustible Cigarette Use

Dermal Cryotherapy for Treatment of Pigmented Lesions

Tobacco Treatment Comparison for Cancer Care

Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women

Efficacy of Cantharidin in Molluscum Contagiosum

Study of the Effect of Individualizing Daytrana Wear-times on Sleep in Children With ADHD

Pre-pubertal Low Dose Transdermal Estradiol in Turner Syndrome

Optical Coherence Tomography Guided C&D

Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection

Focused Ultrasound and Gemcitabine in Breast Cancer

Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma

Visibility of Lesion Characteristics With Phase Contrast Mammography

Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

Low-dose UVA1 Radiation in Cutaneous Lupus Patients

Nano-Pulse Stimulation (NPS) in Sebaceous Hyperplasia Optimization Study

Human Repeat Insult Patch Test of Wound Dressings